08 sep 25   venture life group - directorate change venture life group plc | vlg | 59.5 0 0.0% | mkt cap: 76.2m    rns number : 3044y venture life group plc 08 september 2025   8th september 2025     venture life group plc   ("venture life", "vlg" or the "group")   directorate change   venture life (aim: vlg), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, is pleased to announce the appointment of mr peter jackson to the board of the company as chief digital and technology officer. peter's appointment will take effect from 1 december 2025.   peter is a very experienced global technology leader with over 30 years' experience delivering transformational sales, marketing, erp, crm analytics solutions across fmcg, consumer healthcare, high tech and media sectors. peter has a proven track record of aligning it strategy with business goals to deliver measurable growth, operational efficiency and competitive advantage. he is recognised for building high-performance global teams, forging strong business partnerships and driving digital innovation in complex, multi-region environments. prior to joining vlg, peter was with mccormick & company (part of the mccormick corporation) as global vp, sales & marketing it for over 4 years, and prior to that for 13 years with johnson & johnson consumer care, finishing that time as senior director, customer & sales it, emea.   jerry randall, ceo, commented: "we are absolutely delighted that peter is joining our group, as we continue on our journey of transformational change into a capital light brand focused global consumer healthcare platform, supporting consumers on their journey for proactive healthy longevity. peter has an exceptional track record of aligning it strategy with business goals in multi-region organisations, and i am certain that his extensive experience and expertise will have a dramatic positive effect on our business in the coming years. having integrated digital capabilities with advanced ai & robust data to drive insights is one of our 5 key strategic pillars and having peter in the business will significantly enhance our work on this pillar."     for further information, please contact:   venture life group plc                                                                                                    +44 (0) 1344 578004   jerry randall, chief executive officer daniel wells, chief financial officer   cavendish capital markets limited (nomad and broker)                                             +44 (0) 20 7720 0500    stephen keys/george lawson (corporate finance) michael johnson (sales)    about venture life (www.venture-life.com)   venture life is an international consumer self-care company focused on commercialising products for the global self-care market. headquartered in the uk, the group's product portfolio includes balance activ in the area of women's intimate healthcare, earol® supporting ent care, lift and glucogel product ranges for energy and glucose management and hypoglycaemia, plus the health & her product range supporting the hormonal lifecycle.   the products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. in the uk,  ireland and the usa these are supplied direct by the company to retailers, elsewhere they are supplied by the group's international distribution partners.      regulatory disclosures   save for his upcoming appointment as a director of the company, peter robert jackson, aged 57, does not hold and has not held any other directorships or partnerships in the past five years.   there is no further information on peter jackson required to be disclosed under schedule two, paragraph (g) of the aim rules for companies.               this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   boabbgdcxsgdgur return to news summary

Label: Gesunken